UK Markets open in 1 hr 6 mins

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
48.74-0.10 (-0.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close48.84
Open48.26
BidN/A x N/A
AskN/A x N/A
Day's range48.00 - 48.79
52-week range39.72 - 51.05
Volume1,020,097
Avg. volume1,015,185
Market cap338.98B
Beta (5Y monthly)0.27
PE ratio (TTM)21.68
EPS (TTM)2.25
Earnings dateN/A
Forward dividend & yield1.22 (2.60%)
Ex-dividend date18 Mar 2021
1y target est52.44
  • Globe Newswire

    Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research

    The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. This is the first time that research scientists can conduct oncology research with Foundation Medicine’s comprehensive genomic profiling in their own laboratories to gain meaningful genomic insights and deepen their understanding of cancer biology. This kit is an importan

  • Motley Fool

    Why Atea Pharmaceuticals Stock Got Crushed This Week

    Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

  • Reuters

    Roche's implant for chronic eye disorder wins U.S. approval

    (Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy.